Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)

National Institutes of Health · United States government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

$1.0M
Est. Value
May 07, 2028
Response Due
Active
Status

Opportunity Overview

This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of AD/ADRD.

This is one of 123 active United States Pharmaceuticals opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyNational Institutes of Health
CountryUnited States
CategoryPharmaceuticals
Estimated value$1.0M
NAICS93.866
PublishedDecember 30, 2024
Procurement stageRequest for Proposal (RFP)
Response dueMay 07, 2028
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 12, 2026

Source: U.S. Government (Simpler.Grants.gov) — public domain. Not affiliated with or endorsed by the United States Government.

Related Opportunities in United States

PPVG GEN V Award
National Retardant
PPVG GEN V AWARD SPE2DX25D8000
Febuxostat National Contract
Ziprasidone Capsules
Hydrocodone Acetaminophen
Olanzapine SPE2D2-25-D-0011 Award
Olopatadine HCL 0.1% Ophthalmic Solution

See every United States Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United States Pharmaceuticals intelligence report in your inbox

A personalized report on United States Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.